MTRR rs1532268 polymorphism and gastric cancer risk: evidence from a meta-analysis.

Guping Zhong, Xiaojin Luo, Ji Li, Yuanhang Liao, Guan Gui, Jianwen Sheng

Journal: The Journal of international medical research 2022;50(5):3000605221097486

PMID: 35579185

Abstract

OBJECTIVE

The methionine synthase reductase () gene encodes the MTRR enzyme involved in the metabolic pathway of homocysteine. Several studies investigated the effect of the MTRR rs1532268 gene polymorphism on the risk of gastric cancer (GC), but the results have been inconsistent.

METHODS

We performed a comprehensive and systematic search of PubMed, Google Scholar, MEDLINE, Science Direct, Scopus, CNKI, and Web of Science. Five studies were included in this meta-analysis to determine whether MTRR rs1532268 polymorphism contributes to the risk of GC.

RESULTS

Pooled data indicated that the MTRR rs1532268 polymorphism significantly increased GC risk under the allele comparison model (odds ratio [OR] = 1.14, 95% confidence interval [CI] = 1.01-1.29) and dominant model (OR = 1.14, 95% CI = 1.00-1.30). In the analysis stratified by ethnicity, no relationship was found in Whites or Asians.

CONCLUSION

Our meta-analysis suggests a positive correlation between MTRR rs1532268 polymorphism and GC development.

Address: Department of Gastroenterology, The People's Hospital of Yichun City, Jiangxi, China.; Department of Urology, The People's Hospital of Yichun City, Jiangxi, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.